Despite significant revenue growth and strong cash reserves, Sarepta is facing challenges, including a tragic patient safety event, administrative delays, and a revised revenue forecast. The company is focused on addressing these issues and remains optimistic about future growth.

Company Guidance

In the first quarter of 2025, Sarepta Therapeutics reported $612 million in total net product revenue, marking a 70% increase compared to the same quarter last year. The PMO franchise grew by 5%, reaching $237 million, while ELEVIDYS sales surged by 180% to $375 million. Despite this significant growth, Sarepta fell short of expectations due to several challenges, including administrative issues, a severe flu season, and a safety event that led some families to delay scheduled infusions. Consequently, the company adjusted its annual net product revenue guidance to between $2.3 billion and $2.6 billion across its four approved therapies. Sarepta emphasized its commitment to ensuring patient safety and providing timely education to the physician and patient community to maintain confidence in ELEVIDYS, which has been shown to modify the course of Duchenne muscular dystrophy.

Record Revenue Growth

Sarepta Therapeutics achieved $612 million in total net product revenue in Q1 2025, representing a 70% growth over the same quarter last year.

ELEVIDYS Sales Surge

ELEVIDYS achieved sales of $375 million in the first quarter, representing a 180% increase over the same quarter last year.

PMO Franchise Stability

The PMO franchise grew by 5%, achieving $237 million for the quarter.

Strong Cash Position

Sarepta reported a strong cash position with $647 million in cash, cash equivalents, investments, and restricted cash at the end of Q1 2025.

Sarepta Therapeutics (SRPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.60 / -	0.34	―	―	―
Aug 06, 2025	2025 (Q2)	0.83 / 1.89	0.07	2600.00% (+1.82)	―	―
May 06, 2025	2025 (Q1)	-3.21 / -4.60	0.37	-1343.24% (-4.97)
Feb 26, 2025	2024 (Q4)	1.88 / 1.50	0.47	219.15% (+1.03)
Nov 06, 2024	2024 (Q3)	-0.07 / 0.34	-0.46	173.91% (+0.80)	―
Aug 07, 2024	2024 (Q2)	-0.13 / 0.07	-0.27	125.93% (+0.34)	―
May 01, 2024	2024 (Q1)	0.01 / 0.37	-5.86	106.31% (+6.23)	―
Feb 28, 2024	2023 (Q4)	0.07 / 0.47	-1.24	137.90% (+1.71)	―
Nov 01, 2023	2023 (Q3)	-1.22 / -0.46	-2.94	84.35% (+2.48)	―
Aug 02, 2023	2023 (Q2)	-1.78 / -0.27	-2.65	89.81% (+2.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$16.26	$17.96	+10.46%
May 06, 2025	$46.75	$36.72	-21.45%
Feb 26, 2025	$106.86	$103.06	-3.56%
Nov 06, 2024	$127.97	$120.42	-5.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.